Search hospitals
>
Washington
>
Seattle
University of Washington
Claim this profile
Seattle, Washington 98195
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for HIV Infection
Conducts research for Human Immunodeficiency Virus Infection
Conducts research for Lung Cancer
1050 reported clinical trials
170 medical researchers
Summary
University of Washington is a medical facility located in Seattle, Washington. This center is recognized for care of Cancer, Breast Cancer, HIV Infection, Human Immunodeficiency Virus Infection, Lung Cancer and other specialties. University of Washington is involved with conducting 1,050 clinical trials across 1,749 conditions. There are 170 research doctors associated with this hospital, such as Sabine s Coppieters, MD, Michael J Wagner, MD, Christine Chung, MD, and Petter Bjornstad, MD.
Area of expertise
Cancer
University of Washington has run 83 trials for Cancer. Some of their research focus areas include:
Breast Cancer
University of Washington has run 83 trials for Breast Cancer. Some of their research focus areas include:
Top PIs
Sabine s Coppieters, MD
Investigator site 2 - US0010087
3 years of reported clinical research
Michael J Wagner, MD
Dana-Farber Cancer Institute
6 years of reported clinical research
Christine Chung, MD
Moffitt Cancer Center
1 year of reported clinical research
Petter Bjornstad, MD
Children's Hospital Colorado
1 year of reported clinical research
Clinical Trials running at University of Washington
Prostate Cancer
Breast Cancer
Breast cancer
Ovarian Cancer
Stroke
Multiple Myeloma
Follicular Lymphoma
Brain Tumor
Esophageal Carcinoma
Asthma
Shorter vs Usual Radiation Therapy
for Prostate Cancer
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.
Recruiting
2 awards
Phase 3
10 criteria
PF-06821497 + Enzalutamide
for Prostate Cancer
Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment. The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.
Recruiting
2 awards
Phase 3
5 criteria
Apalutamide + Targeted Radiation
for Prostate Cancer
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting
2 awards
Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of Washington?
University of Washington is a medical facility located in Seattle, Washington. This center is recognized for care of Cancer, Breast Cancer, HIV Infection, Human Immunodeficiency Virus Infection, Lung Cancer and other specialties. University of Washington is involved with conducting 1,050 clinical trials across 1,749 conditions. There are 170 research doctors associated with this hospital, such as Sabine s Coppieters, MD, Michael J Wagner, MD, Christine Chung, MD, and Petter Bjornstad, MD.
Where is University of Washington located?
The University of Washington Hospital is situated at 1959 N.E. Pacific Street, Seattle, Washington, near the University of Washington campus. For access via Interstate 5, use Exit 168B (Bellevue/State Route 520) eastbound, then take the Montlake Boulevard exit, following signs to UW Medical Center. From Interstate 405, utilize Exit 14 (Seattle via Evergreen Point Bridge, State Route 520) westbound, then proceed to the Montlake Boulevard exit, adhering to signs directing to UW Medical Center.
Who should I call to ask about financial aid or insurance network?
For financial assistance at the University of Washington Hospital: - Contact the Patient Financial Services Department at 866.245.4373, available Monday through Friday during business hours. - For needs-based financial assistance applications, call UW Medicine at 206.598.1950 or toll-free at 1-877-780-1121. - For insurance-related inquiries and assistance with applying for insurance post-discharge, contact UWMC Financial Counseling at 206.598.4388.
What insurance does University of Washington accept?
The University of Washington accepts a range of insurance plans such as Aetna, Blue Cross Blue Shield, Premera Blue Cross, Regence Blue Cross, Tricare, and United Healthcare. Coverage includes gender affirming care in compliance with Washington state law, which mandates insurance companies to provide coverage for gender affirming treatment when medically necessary. Patients are advised to confirm their coverage specifics with their insurance provider and consult their healthcare provider for detailed information.
What awards or recognition has University of Washington received?
The University of Washington Hospital, located in Seattle, Washington, is renowned for being the top-ranked healthcare and social organization in the state and the third-best place to work in the region. It actively supports undergraduate research via the Population Health Initiative, awarding students for projects on critical issues like air pollution, vaccine hesitancy, and healthcare for marginalized populations, with 20 students recognized in 2022 and 12 in 2021.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.